Pulmocide
Updated: April 24, 2026
Dan Burgess, CEO
Country: UK | Funding: $205.5M (+)
Founded: 2013
Website: https://www.pulmocide.com
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
Founded: 2013
Website: https://www.pulmocide.com
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
